SL43
SL43 is an orally active and potent SOS1 inhibitor with a Kd of 0.16 μM. SL43 disrupts SOS1-KRAS interaction, inhibits SOS1-mediated nucleotide exchange on KRAS mutants, and suppresses RAS-MAPK signaling. SL43 exerts antiproliferative activity against KRAS-mutant cancer cells, induces early apoptosis and G1 phase cell cycle arrest, and reduces phosphorylated MEK and ERK levels. SL43 suppresses tumor growth in a colorectal cancer xenograft model.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C27H33ClN4
- 分子量:449.03
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MEK アイソフォーム固有の製品をすべて表示
More
生物活性
|
K-RAS |
SL43 binds to SOScat with a Kd of 0.16 μM, indicating high affinity for the SOS1 catalytic domain[1].
SL43 potently disrupts the SOS1-KRASG12C interaction with an IC50 of 13.0 nM[1].
SL43 preferentially inhibits SOS1-mediated nucleotide exchange on KRASG12C, KRASG12V, and KRASG12D mutants with IC50 values ranging from 13.4-29.1 nM, while showing weaker inhibition of KRASWT (IC50 = 95.8 nM)[1].
SL43 (120 h) potently and selectively inhibits the proliferation of KRAS-mutant CRC cell lines (IC50 = 0.028-0.238 μM) with over 100-fold selectivity over KRAS wild-type CRC cell lines (IC50 = 2.495-4.520 μM)[1].
SL43 (10-40 nM; 72 h) dose-dependently suppresses colony formation in SW620 and HCT116 KRAS-mutant CRC cell lines[1].
SL43 (200-800 nM; 48 h) dose-dependently induces early apoptosis and G1 phase cell cycle arrest in SW620 and HCT116 KRAS-mutant CRC cell lines[1].
SL43 (50-200 nM; 48 h) dose-dependently inhibits the RAS-MAPK signaling pathway in SW620 and HCT116 KRASG12D/G13D CRC cell lines by reducing phosphorylated MEK and ERK levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:KRAS-mutant CRC cell lines (SW620/G12V, HCT116/G13D)
-
Concentration:200, 400, 800 nM
-
Incubation Time:48 h
-
Result:Significantly increased the proportion of early apoptotic cells, with high-concentration groups reaching 35.47% in SW620 cells and 25.97% in HCT116 cells.
-
Cell Line:KRAS-mutant CRC cell lines (SW620/G12V, HCT116/G13D)
-
Concentration:200, 400, 800 nM
-
Incubation Time:48 h
-
Result:Induced dose-dependent G1 phase cell cycle arrest, with the G1 population increasing from 64.13% to 78.04% in SW620 cells and from 35.34% to 57.59% in HCT116 cells.
-
Cell Line:KRAS-mutant CRC cell lines (SW620/G12V, HCT116/G13D)
-
Concentration:50, 100, 200 nM
-
Incubation Time:48 h
-
Result:Led to a concentration-dependent decrease in p-MEK and p-ERK levels in both SW620 and HCT116 cells.
Left total MEK and ERK expression unaltered.
SL43 (400-800 mg/kg; p.o.; single dose) has a favorable safety profile in BALB/c mice, with an estimated oral median lethal dose (LD50) exceeding 800 mg/kg[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Colorectal cancer BALB/c nude mice (female, 6-8 weeks old, 20-22 g, subcutaneous inoculation of HCT116 KRASG13D cells)[1]
-
Dosage:20 mg/kg; 40 mg/kg
-
Administration:p.o.; daily; 18 days
-
Result:Produced a tumor growth inhibition (TGI) rate of 57.2% at 20 mg/kg.
Produced a tumor growth inhibition (TGI) rate of 74.9% at 40 mg/kg.
Induced no significant body weight loss or observable histological alterations in major organs (heart, liver, spleen, lungs, kidneys) at either dose.
化学情報
-
分子量 449.03
-
分子式 C27H33ClN4
-
SMILES
ClC1=CC=C([C@@H](C)NC2=NC(NCC(C)(C)C)=NC3=CC=C(C4=CCCCC4)C=C23)C=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
SL43 関連分類
HY-183365 関連分類
Powered by Bioz